The Shielded Living Therapeutics™ platform

1. Cell

2. Sphere

3. Manufacturing

  • 1 Cell

    Sigilon has developed proprietary engineered human cells that:

    • Express high levels of desired protein(s)
    • Deliver proteins at a constant rate or are programmed to “sense and respond” to the changing environment
    • Survive well in an encapsulation environment
    • Can be produced at large scale
    • Are similar to cells previously used in clinical applications
    • Provide the ability to easily insert new gene expression cassettes for different applications
  • 2 Sphere

    The sphere is composed of our proprietary Afibromer™ matrix, which exhibits ideal properties for housing thousands of therapeutic cells. Building upon foundational discoveries made at MIT, Sigilon has developed this dual-layer sphere that can remain in the body while generating minimal fibrosis or immune rejection.

    1) Outer layer with Afibromer™
    • Preventing immune response and fibrosis
    • Allowing influx of nutrients and efflux of protein

    2) Inner compartment
    • Optimized for viability and productivity

  • 3 Manufacturing

    Sigilon has created a state-of-the-art manufacturing platform that is modular for all potential product candidates developed. With virtually all aspects of the platform shared across the development programs, our manufacturing process is designed for reproducibility, speed and cost-efficiency, with the hopes of providing a true “off-the-shelf” product for patients.

In preclinical studies, components of our product candidates were well-tolerated with no notable adverse effects for up to 12 months. In addition, the spheres were successfully retrieved and redosed.

Shielded Living Therapeutics™ products potentially capture benefits beyond existing therapies